About US
Contact us
-
Psoriasis study does little to help Pfizer with XeljanzAnalyst sees side effects putting off 'risk-averse dermatology community' Rheumatoid arthritistreatmentXeljanz, while expected to grow into a big seller for Pfizer ($PFE), hasn't had a fast start. Th2013/10/11
-
Merck Serono's new HQ taps open-office style to encourage innovationMerck Seronoopened its new global headquarters in Darmstadt, Germany, after shuttering a co-HQ in Geneva last year. The redesigned buildings onMerck KGaA's campus feature the sort of flexible work sta2013/10/10
-
Teva plots 5,000 more job cuts in $2B savings driveTeva Pharmaceutical Industries is already in the middle of a big cost-cutting push. And it's about to get bigger. The Israel-based generics giant ($TEVA) plans to lay off up to 5,000 people, or about2013/10/10
-
Bayer's now-approved Adempas girds for market-share battle in PAHBayerscored another R&D success with the FDA approval of Adempas (riociguat) for two rare pulmonary disorders. It's the first of a new generation of drugs for pulmonary arterial hypertension, and2013/10/10
-
Former Lilly scientists indicted for passing R&D secrets to Chinese drugmakerTwo former Eli Lilly ($LLY) scientists stand accused of passing laboratory trade secrets to a Chinese drugmaker. Guoqing Cao and Shuyu "Dan" Li are held without bail in Indiana, where they were indict2013/10/9
-
GlaxoSmithKline to seek EMA approval for 2015 malaria vaccine launchGlaxoSmithKline's ($GSK) experimentalmalariavaccine may not have delivered results as strong as the company hoped. But it does offer enough protection to slash the number of cases in infants for a tim2013/10/9
-
Merck puts Whitehouse Station HQ on the blockMerck's global headquarters is wearing a "For Sale" sign. The company said last year that it would pack up and leave Whitehouse Station, NJ, in a money-saving move. But now, the million-square-foot ca2013/10/8
-
Forget a Roche merger; Novartis sell-offs could be imminent, analyst saysConsumer health, animal health, vaccines and diagnostics all on the table, with decision expected soon News flash from Basel: Yes, Novartis really is considering selling off a few of its units, in de2013/10/8
-
U.K.'s nod to J&J's Caelyx comes even as shortages expectedJanssen has warned docs to expect shortages starting next month The U.K. drug price watchdog today gave Johnson & Johnson's ($JNJ) Caelyx the distinction of being one of only two drugs it believe2013/9/30
-
FTC tells Mylan to sell 11 drugs to complete $1.6B Agila dealTheU.S. Federal Trade Commissionfavors Mylan's ($MYL) $1.6 billion buyout ofAgila Specialties, but is insisting the companies sell off 11 injectable drugs in markets where it believes the deal would h2013/9/30